Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7297876 | 0.84 | HPGD (0.37) | HPGDKMT2ANPC1PTGS2MAOA | |
| SCHEMBL7297885 | 0.82 | HPGD (0.40) | HPGDKMT2ANPC1PTGS2MAOA | |
| SCHEMBL10060475 | 0.82 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1811878 | 0.76 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3626861 | 0.76 | KMT2A (0.34) | HPGDKMT2ANPC1PTGS2MAOA | |
| SCHEMBL3628951 | 0.76 | HDAC8 (0.36) | HPGDKMT2ANPC1MAOAMAOB | |
| SCHEMBL10060466 | 0.75 | CA12 (0.46) | LMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL778854 | 0.75 | HTR6 (0.50) | LMNASMN1; SMN2CYP2C19ALDH1A1 | |
| Water SCHEMBL28020891 | 0.74 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL8235601 | 0.74 | NAPRT (0.57) | KMT2APTGS2CYP3A4NFE2L2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198237-A1 | PIPERIDINES AS MENIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210115018-A1 | PIPERIDINE COMPOUNDS AS COVALENT MENIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-04-22 | — | — | US | disclosed |
| US-8288406-B2 | Hydroxymethylcyclohexylamines | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20110059999-A1 | Hydroxymethylcyclohexylamines | Grünenthal GmbH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-7101892-B2 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. | 2006-09-05 | — | — | US | disclosed |
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198237-A1 | PIPERIDINES AS MENIN INHIBITORS | MEN1, WFS1, BRCA1 | HPGD 2157/4885KMT2A 977/4885NPC1 1174/4885 |
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | HTR7, HTR2C, HTR1A | HPGD 3454/4885KMT2A 2168/4885NPC1 3025/4885 |
| US-20110059999-A1 | Hydroxymethylcyclohexylamines | OPRL1, OPRM1, OPRD1 | HPGD 1870/4885KMT2A 1124/4885NPC1 2702/4885 |
| US-20210115018-A1 | PIPERIDINE COMPOUNDS AS COVALENT MENIN INHIBITORS | MEN1, BRCA1, PRMT1 | HPGD 3532/4885KMT2A 175/4885NPC1 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.